Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma
Completed · Phase 2 · NCT03361748
Conditions: Multiple Myeloma
At a glance
- Research payments reported, 2025
- $168,008
- U.S. investigators named
- 5
- Sites paid
- 5
- Planned or actual enrollment
- 149
About the trial
- Sponsor
- Celgene
- Tested
- bb2121 (biological)
- Dates
- Started 2017-12-13; completion 2023-12-20
- Results posted
- Yes
This is an open label, single-arm, multicenter, Phase 2 study to evaluate the efficacy and safety of bb2121 in subjects with relapsed and refractory multiple myeloma. A leukapheresis procedure will be performed to manufacture bb2121 chimeric antigen receptor (CAR) modified T cells. Prior to bb2121 infusion subjects will receive lymphodepleting therapy with fludarabine and cyclophosphamide.
From ClinicalTrials.gov, last updated 2025-05-23. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Celgene Corporation reported $168,008 in research payments for this study in 2025 (5 payments).
Products named: Abecma
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Nikhil C. Munshi, MD Medical Oncology · Boston, MA
- Yi Lin, M.D. Hematology · Rochester, MN
- David S. Siegel, MD Medical Oncology · Hackensack, NJ
- Sundar Jagannath, M.D. Medical Oncology · New York, NY
- Jesus G. Berdeja, M.D. Hematology & Oncology · Nashville, TN
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Hackensack University Medical Center, NJ $125,539
- Sarah Cannon Research Institute, Llc $27,093
- Mayo Clinic Sports Medicine $5,996
- Mount Sinai School of Medicine $5,155
- Dana-Farber Cancer Institute $4,225
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.